PDE5 inhibitors can improve laboratory measures of endothelial function in some studies, but they are not proven preventive heart medicines for the general ED population.
What studies have measured
Research has examined flow-mediated dilation and other vascular markers before and during PDE5-inhibitor treatment. Reviews describe improvements in some endothelial measurements, especially during continued treatment.
A plausible mechanism is not the same thing as a proven patient benefit. The stronger the claim, the stronger the clinical evidence should be.
Keep the indication and the outcome separate. Evidence that a medicine improves a questionnaire score, blood-flow marker, or symptom during active treatment does not automatically show permanent recovery, disease prevention, or benefit in people without the condition studied.
What the studies do not establish
A better surrogate marker does not prove that an ED prescription prevents heart attacks, strokes, or cardiovascular death. Observational studies reporting better outcomes among users can be distorted by who receives and safely uses the drugs.
Keep the indication and the outcome separate. Evidence that a medicine improves a questionnaire score, blood-flow marker, or symptom during active treatment does not automatically show permanent recovery, disease prevention, or benefit in people without the condition studied.
ED as a health signal
The more actionable cardiovascular benefit may be diagnostic attention: a new ED complaint can prompt evaluation of blood pressure, diabetes, lipids, smoking, sleep apnea, exercise tolerance, and medication effects.
Keep the indication and the outcome separate. Evidence that a medicine improves a questionnaire score, blood-flow marker, or symptom during active treatment does not automatically show permanent recovery, disease prevention, or benefit in people without the condition studied.
Why nitrates remain a hard stop
A theory about blood-vessel benefit does not make PDE5 inhibitors safe with nitroglycerin, isosorbide, or recreational nitrites. The combination can cause dangerous hypotension.
Keep the indication and the outcome separate. Evidence that a medicine improves a questionnaire score, blood-flow marker, or symptom during active treatment does not automatically show permanent recovery, disease prevention, or benefit in people without the condition studied.
The right framing
Treat ED appropriately, assess cardiovascular risk, and improve modifiable risk factors. Do not take sildenafil or tadalafil as a heart-health supplement or replace proven cardiovascular treatment with an exploratory mechanism.
Keep the indication and the outcome separate. Evidence that a medicine improves a questionnaire score, blood-flow marker, or symptom during active treatment does not automatically show permanent recovery, disease prevention, or benefit in people without the condition studied.
Get ED and cardiovascular risks reviewed together
Review the current medication, dose, eligibility, pharmacy, total price, and renewal terms. Prescription approval is not guaranteed.
VIEW CURRENT OPTIONPaid affiliate link · Tracking destination verified July 19, 2026
Frequently asked questions
Can tadalafil prevent a heart attack?
That has not been established for routine ED treatment.
Does better endothelial function mean healthier arteries?
It may be a favorable physiological marker, but clinical outcomes matter more.
Should ED trigger a heart check?
Persistent or new ED can justify cardiovascular risk assessment, especially with other risk factors.
Research and official sources
- Review of endothelial effects
- Review of PDE5 inhibitors and endothelial function
- 2023 endothelial-function pilot study
EdClinic prioritizes randomized trials, systematic reviews, FDA or NIH materials, and direct prescribing information. Study populations, doses, endpoints, and conflicts should be checked before converting a result into consumer advice.